Innervate Radiopharmaceuticals Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Investors
  • 2

Innervate Radiopharmaceuticals General Information

Description

Developer of positron emission tomography (PET) imaging and therapeutic radiopharmaceuticals intended to improve image resolution. The company offers an imaging biomarker that has significant advantages over single photon emission computed tomography (SPECT), the current standard of care for biomarker imaging in neuroblastoma patients, enabling the healthcare industry to improve reliability and accuracy in the detection of disease, in turn, leading to important improvements in patient management and outcomes for patients with neuroblastoma and potentially other diseases.

Contact Information

Formerly Known As
Fluoro Diagnostics, Illumina Radiopharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 175 Elm Road
  • Englewood, NJ 07631
  • United States
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 175 Elm Road
  • Englewood, NJ 07631
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innervate Radiopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 05-Mar-2026 In Progress Generating Revenue
3. Later Stage VC 20-Mar-2025 Completed Clinical Trials - Phase 3
2. Seed Round 14-Jan-2022 $250K Completed Stealth
1. Angel (individual) 04-Jun-2019 $250K $250K Completed Stealth
To view Innervate Radiopharmaceuticals’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Innervate Radiopharmaceuticals Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mountain State Capital Venture Capital Minority
Robin Hood Ventures Angel Group Minority
To view Innervate Radiopharmaceuticals’s complete investors history, request access »

Innervate Radiopharmaceuticals FAQs

  • When was Innervate Radiopharmaceuticals founded?

    Innervate Radiopharmaceuticals was founded in 2019.

  • Where is Innervate Radiopharmaceuticals headquartered?

    Innervate Radiopharmaceuticals is headquartered in Englewood, NJ.

  • What industry is Innervate Radiopharmaceuticals in?

    Innervate Radiopharmaceuticals’s primary industry is Drug Discovery.

  • Is Innervate Radiopharmaceuticals a private or public company?

    Innervate Radiopharmaceuticals is a Private company.

  • What is Innervate Radiopharmaceuticals’s current revenue?

    The current revenue for Innervate Radiopharmaceuticals is .

  • How much funding has Innervate Radiopharmaceuticals raised over time?

    Innervate Radiopharmaceuticals has raised $250K.

  • Who are Innervate Radiopharmaceuticals’s investors?

    Mountain State Capital and Robin Hood Ventures have invested in Innervate Radiopharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process